Company Mission
To discover, develop, and commercialize proprietary, safe and effective, evidence-based natural therapeuticals that prevent disease and maintain good health.

Company History
Afexa Life Sciences, an international biotechnology company, was founded in 1992 as a spin-off from the University of Alberta. Over 12 years, involving investments in excess of $20 million, its 25 member scientific team discovered and developed a selection of proprietary natural products. It also developed an internationally recognized and patented technology – ChemBioPrint® – which is both a discovery and standardization tool.

The ChemBioPrint Process
ChemBioPrint is the only process that accurately characterizes natural mixtures assuring batch-to-batch consistency, efficacy and safety. It precisely identifies the chemical profile and biological activity of natural health products. This is a combination of chemical and pharmacological fingerprinting that ensures each batch of products delivers verifiable and provable health benefits and is both safe and consistent with previous batches. ChemBioPrint represents a major scientific breakthrough in the discovery and standardization of nutraceuticals opening the door to increased consumer confidence in natural health products and paving the way for ground-breaking regulatory approval of medical claims involving natural products which offer the same degree of scientifically verifiable consistency, safety and efficacy as synthetic drugs.

The Products
The Afexa Life Sciences team including 13 PhDs and 2 MDs with expertise in various scientific disciplines ranging from natural product chemistry, phytomedicine, pharmacology, immunology, cardiovascular system and central nervous system used ChemBioPrint to develop COLD-FX® to support and stimulate the immune system; REMEMBER-FX® to relieve brain fatigue and improve memory; CELL-FX® to soothe sore joints and normalize cell growth. These nutraceuticals have gone through numerous clinical trials in Canada and the U.S.